Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   201 Trials   201 Trials   5390 News 


12345678910111213...6970»
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical data, Retrospective data, Journal, Real-world evidence, Real-world:  Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early-stage breast cancer: An Australian institutional real-world experience. (Pubmed Central) -  Jun 20, 2024   
    Our study showed that TDM-1 was also effective in patients using pertuzumab, contributes significantly to PFS when used in the second line compared to its use in the later line, and does not make any difference in OS. This study demonstrates that de-escalated adjuvant treatment for HER2-positive early breast cancer achieved favourable pathological and long-term outcomes comparable to large trials, some utilising more intensive chemotherapeutic components.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. (Pubmed Central) -  Jun 14, 2024   
    It is well known that p-AKT expression is linked to an unfavorable prognosis, and the phosphatidylinositol-3-kinase (PI3K)/AKT pathway, as the most common mutated pathway in breast cancer, plays a major role in the mechanism of drug resistance. Therefore, in the current review, we summarize the molecular alterations present in HER2-positive breast cancer, elucidate the relationships between HER2 overexpression and alterations in the PI3K/AKT signaling pathway and the pathways of the alterations in breast cancer, and summarize the resistant mechanism of drugs targeting the HER2-AKT pathway, which will provide an adjunctive therapeutic rationale for subsequent resistance to directed therapy in the future.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  Structure and conformational variability of the HER2-trastuzumab-pertuzumab complex. (Pubmed Central) -  Jun 9, 2024   
    Notably we obtain our best data with ultra-thin continuous carbon grids, showing that with current cameras their use to alleviate particle misdistribution is compatible with a protein complex of only 162?kDa. Perhaps most importantly, we provide here a dataset for such a smallish protein complex for further development of software accounting for continuous conformational heterogeneity in cryo-EM images.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Preclinical, Review, Journal:  Mechanisms of Acquired Resistance to HER2-Positive Breast Cancer Therapies Induced by HER3: A Comprehensive Review. (Pubmed Central) -  Jun 9, 2024   
    The review also explores the resistance mechanisms associated with various drugs, including trastuzumab, lapatinib, and PI3K inhibitors, providing insights into the intricate molecular processes underlying resistance development. The review concludes by emphasizing the necessity for further clinical trials to assess the efficacy of HER3 inhibitors and the potential of developing safe and effective anti-HER3 treatments to improve treatment outcomes for patients with HER2-positive breast cancer.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Biomarker, Enrollment open:  INNOVATE: BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer (clinicaltrials.gov) -  Jun 6, 2024   
    P2,  N=28, Recruiting, 
    The review concludes by emphasizing the necessity for further clinical trials to assess the efficacy of HER3 inhibitors and the potential of developing safe and effective anti-HER3 treatments to improve treatment outcomes for patients with HER2-positive breast cancer. Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    These findings provide evidence to support echocardiographic surveillance for several years after cardiotoxic therapy and also suggest a need to examine the efficacy of management of cardiovascular risk factors to mitigate risk. Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal, Metastases:  A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer. (Pubmed Central) -  May 29, 2024   
    GDF-15 is a candidate biomarker for increased risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy. Aim: This systematic literature review aims to summarize the efficacy/effectiveness of treatments, including eribulin (ERI)-based and anti-human epidermal growth factor receptor 2 (HER2) treatments in advanced/metastatic HER2+ breast cancer...Longer overall survival (OS) was associated with 1L and 2L treatment, and for 3L+ studies that included ERI, ERI or trastuzumab (Tmab)
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal, IO biomarker:  Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodies. (Pubmed Central) -  May 21, 2024   
    After optimizing the relevant assay parameters, the established RGA was fully validated based on ICH-Q2 (R1), which demonstrated that the method had excellent specificity, accuracy, precision, linearity, and stability. In summary, this robust and innovative bioactivity determination assay can be applied in the development and screening, release control, biosimilar assessment and stability studies of anti-HER2 mAbs.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Journal:  Assessment of genetic and clinical factors in T2D susceptibility among patients with hypertension. (Pubmed Central) -  May 20, 2024   
    Incorporating clinical and genetic screening into risk assessment is important for the detection and prevention of T2D in patients with HTN. The detected SNPs (rs7865889, rs12737517, and rs10896290), especially the protective SNP (rs12737517), provide an opportunity for better diagnosis, prevention, and therapy of patients with T2D and HTN.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Journal:  Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors. (Pubmed Central) -  May 16, 2024   
    Notably, pyrotinib plus trastuzumab was more effective than trastuzumab plus pertuzumab in inhibiting tumor growth and HER2 downstream pathways in HER2+ breast cancer with primary resistance to trastuzumab. These findings support clinical testing of the therapeutic efficacy of dual anti-HER2 treatment combining an intracellular small molecule with an extracellular antibody.
  • ||||||||||  Review, Journal, Metastases:  HER2-Positive Metastatic Colorectal Cancer. (Pubmed Central) -  May 9, 2024   
    Trastuzumab plus lapatinib, trastuzumab plus pertuzumab, and trastuzumab deruxtecan (T-DXd) also have evidence of efficacy in this setting...These include the optimal sequence of anti-HER2 therapies with chemotherapy and anti-EGFR therapies, the optimal combination partners for anti-HER2 therapies, and the incorporation of predictive biomarkers to guide use of anti-HER2 therapies. Results of ongoing studies may thus alter the treatment paradigm above in the coming years.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Radioimmunotherapy of HER2-positive breast cancer using 225Ac-labeled trastuzumab and 67Cu-labeled pertuzumab biparatopic radioimmunoconjugates (717AB (Convention Center); In-Person) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_1988;    
    Biparatopic combination of macropa-trastuzumab and NOTA-pertuzumab had a better internalization profile in vitro compared with either antibody used singly. Monotherapy of [225Ac]Ac-macropa-trastuzumab or [67Cu]Cu-NOTA-pertuzumab was more effective than the unlabeled antibodies and we anticipate better therapeutic effects using combination of both radiolabeled antibodies in ongoing experiments.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    Enrollment change, Combination therapy:  Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC (clinicaltrials.gov) -  May 6, 2024   
    P2,  N=19, Active, not recruiting, 
    Monotherapy of [225Ac]Ac-macropa-trastuzumab or [67Cu]Cu-NOTA-pertuzumab was more effective than the unlabeled antibodies and we anticipate better therapeutic effects using combination of both radiolabeled antibodies in ongoing experiments. N=33 --> 19
  • ||||||||||  Nerlynx (neratinib) / Puma
    Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer? () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6771;    
    In contrast, neratinib penetrates the BBB well, and its combination with capecitabine produces responses in intensively pretreated patients, especially in cases where the only site of disease progression is the CNS... Neratinib, has shown that it was able to prevent brain metastases and demonstrated benefit in recurrence - free survival and event-survival in combination with Trastuzumab and Docetaxel over (PT+Dtx) for patients without brain metastases.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6219;    
    Pyrotinib and trastuzumab synergistically achieve the comprehensive blockade of HER signaling pathway in HER2-dependent breast cancer. Patients with advanced HER2-positive breast cancer, who are addicted to HER2 signaling cascade, could be considered for pyrotinib in combination with trastuzumab and docetaxel as an alternative first line treatment.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trends in the management of small HER2-positive breast cancers. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5189;    
    Although NAT witnessed an upward trend from 2018 to its peak in 2021, its utilization declined again in 2022. A balance between the most effective treatment and minimizing toxicities should be ensured.